Ebola vaccine shows promise for HIV-Positive individuals
NCT ID NCT03031912
First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This study tested an Ebola vaccine (V920) in 251 HIV-infected adults and adolescents to see if it is safe and triggers an immune response. Participants were randomly assigned to receive the vaccine or a placebo. The trial found that the vaccine produced antibodies against Ebola with manageable side effects, offering hope for protecting this vulnerable group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUM
Montreal, Quebec, H2X 0A9, Canada
Conditions
Explore the condition pages connected to this study.